Hemorrhagic Cystitis Clinical Trial

Hemorrhagic Cystitis, also called Radiation Cystitis when occurring after pelvic radiation

Lipella recently completed a phase-2a, dose-escalation clinical trial evaluating LP-10 (liposomal tacrolimus) for the treatment of hemorrhagic cystitis. Results are published in the peer-reviewed journal, International Urology and Nephrology. Lipella has received US-FDA Orphan Designation for this product.

Radiation used to treat prostate, colon, uterine, cervical and other pelvic cancers can cause chronic, painful urinary inflammation and blood loss called hemorrhagic cystitis. The blood loss, associated with hemorrhagic cystitis and radiation cystitis can lead to surgery, and can be fatal.

  • There are approximately one million cancer survivors in the U.S. that have received pelvic radiation therapy for malignancies of the prostate, uterine, cervix, or colon.
  • Hemorrhagic cystitis and radiation cystitis are associated with significant morbidity and mortality and yet there are currently no FDA approved drug treatment.
  • Hemorrhagic cystitis and radiation cystitis patients suffer highly debilitating symptoms including blood in the urine that can lead to clotting, pain in the bladder, and urinary incontinence.

For more information on the hemorrhagic cystitis and radiation cystitis clinical trial, please see clinicaltrials.gov, call 412-894-1853 or email this address.

Expanded Access Policy

Hemorrhagic Cystitis, Uncontrolled Urinary Blood Loss

Hemorrhagic cystitis is a serious, life-threatening bladder damage from pelvic radiation therapy and/or bladder-toxic chemotherapy.

Hemorrhagic Cystitis Clinical Trial